SCHEMBL6319636

SCHEMBL6319636

COCCOCc1c(C=O)sc2c(=O)c(C(=O)NCc3ccc(Cl)cc3)cn(C)c12

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.48
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318076 0.92 KCNH2 (0.47) KCNH2
SCHEMBL6318379 0.89 KCNH2 (0.48) KCNH2MAPT
SCHEMBL6318334 0.87 KCNH2 (0.53) KCNH2MAPT
SCHEMBL6318103 0.87 KCNH2 (0.53) KCNH2MAPT
SCHEMBL6320816 0.81 KCNH2 (0.47) KCNH2MAPT
SCHEMBL6320713 0.79 KCNH2 (0.51) KCNH2
SCHEMBL6318282 0.79 KCNH2 (0.51) KCNH2
SCHEMBL6321741 0.78 KCNH2 (0.61) KCNH2
SCHEMBL6398796 0.77 KCNH2 (0.51) KCNH2MAPT
SCHEMBL6319327 0.77 KCNH2 (0.51) KCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184370-B1 Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 2005-09-14 EP disclosed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6894050-B2 5-HT receptor ligands and uses thereof PFIZER INC. (US) 2005-05-17 US disclosed
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
EP-1184370-A2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
US-6127341-A AMINOMETHYL-N-(1-((2-(2-THIENYL)-1-(1-CARBAMOYL-5 -AMINOPENTYLCARBAMOYL)ETHYL)-N-METHYLCARBAMOYL)-2-(2 -NAPTHYL)ETHYL)BENZAMIDE, FOR EXAMPLE; ADMINISTERING TO STIMULATE GROWTH, MILK OR WOOL PRODUCTION IN ANIMALS NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-6127354-A FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-1005484-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 2000-06-07 EP disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
US-5922770-A NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 1999-07-13 US disclosed
WO-1998058950-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-12-30 WO disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 KCNH2 1328/4885MAPT 4183/4885
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 KCNH2 491/4885MAPT 3255/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR KCNH2 1469/4885MAPT 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.